AMEA
Surveillance testing is timed to detect recurrence sooner, with suggested testing every 3 months for 2 years followed by every 6 months for 3 years.1
*Note that this is provided as a general guidance and physicians may choose different timings or choice of test at their discretion for each patient.
†Recommended to be done 3-6 months if not performed pre-operatively because of an obstructing lesion. Repeat colonoscopy is recommended to be every 3 years, and then every 5 years thereafter.
CEA, carcinoembryonic antigen; CT, computerized tomography; H&P, history and physical examination.
Important note: Guardant Reveal was developed as a Laboratory Developed Test (LDT), and its performance characteristics determined, by the Guardant Health Clinical Laboratory in Redwood City, CA, USA, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing. This test has not been cleared or approved by the US FDA.